Positive results in uPAR-PET/MR Phase II study in brain cancer
· uPAR-PET with [68]Ga-NOTA-AE105 (now known as uTRACE[®]) was highly prognostic both regarding progression-free survival and overall survival. · 94% of glioblastomas (WHO grade 4 gliomas) in the study were uPAR-PET positive underlines validity of using this target for improved diagnosis and categorisation. · Together with our recently reported positive preclinical data on therapy with uTREAT[®] in glioblastoma, this strongly supports our ambition to pursue a theranostic approach using uTRACE[®] and uTREAT[®] in glioblastoma patients. Copenhagen, Denmark, June 29, 2023 - Curasight A/